If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Cristália launches Lunah in Brazilian market

    Quick Contact
    • Nemera
    Cristália launches Lunah in Brazilian market
    South America, Brazil, Health, Pharmaceuticals

    Cristália, one of the largest pharmaceutical companies in Brazil, launched LUNAH, a preservative-free artificial tears, through its ophthalmology division Latinofarma.

    Announced in an online event for 2,000+ physicians, LUNAH was launched in the brazilian market in two concentrations of hyaluronic acid, bringing relevant benefits in its formulation.

    LUNAH is the company’s first preservative-free artificial tear, and is the result of a partnership between the laboratory and NEMERA, the world leader in the development and production of drug delivery devices for pharmaceutical industries.

    The product reinforces Cristália’s commitment to innovation and the development of products that contribute to an improvement in people’s quality of life.

    “Lunah was developed with science and technique, focusing on the quality of hyaluronic acid, from the source of the polymer, to ideal viscosity and molecular weight, one of the most important attributes for the treatment of patients with dry eye. Delivered to the consumer in Novelia®, a safe and easy to use multi-dose bottle, Lunah unites technology, quality, innovation and a good cost, democratizing the use of preservative-free eye drops in the Brazilian market”, says Ricardo Pacheco, Chairman at Cristália.

    See also

    Nemera's RetroNose enhances therapeutic efficacy of nasal treatments

    The number of applications through the nasal route is expanding, either for local treatments (e.g. chronic rhinosinusitis) or for systemic treatments (e.g. migraine, etc.). The clinical efficacy of a nasal treatment depends on how it is deposited in the nose, because the pharmaceutical target (local, systemic, brain) is directly related to a specific nasal anatomical site. That’s why Nemera has collaborated with CEPR to develop a different and portable delivery technology called RetroNose for a better drug deposition in the distal region of the nose, without lung deposition.

    e-Novelia wins the ‘Excellence in Pharma: Drug Delivery Devices’ award at CPhI Worldwide 2018

    On October 9th, during the CPhI Pharma Awards Gala, e-Novelia®, Nemera’s electronic add-on for ophthalmic droppers, was celebrated as the best-in-class innovation displayed at the show for “Excellence in Pharma: Drug Delivery Devices”. e-Novelia®, Nemera’s smart ophthalmic add-on, has been designed to make patients’ life easier, by offering increased comfort and optimized adherence to their treatments.

    Safelia 1ml and 2.25ml autoinjectors designed to be patient and syringe friendly

    Nemera’s new generation 2-step autoinjector platforms are suitable for fluid to highly viscous injections. Safelia® has been designed to ease patient self-injection experience and to deliver even the most challenging drugs (viscous formulations up to several Centipoise, sustain released, concentrated, fragile and shear sensitive formulations, either in subcutaneous or intramuscular layers, on two platforms: up to 1ml or up to 2.25ml delivery).

    • Brand Launch
    • English
    • Modified 05 Aug 2021
    • Hits 757
    Axium Packaging
    Adequate Packaging
    NF Beauty Group